Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease? Fatih Albayrak, Mustafa Gür, Ahmet Karataş, Süleyman Serdar Koca, Bünyamin Kısacık

When to start secukinumab treatment in patients with axial spondyloarthropathy: Before or after anti-TNFα treatment? Tumay Ak, Leyla Mustafayeva, Yeliz Celik, Ali Yagiz Ayla, Serdal Ugurlu

A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis Alberto Jiménez-Morales, Rafael Cáliz, Susana Aceituno, Miriam Prades, Carles Blanch